Back to database

SS-31

Also known as: Elamipretide, Bendavia, MTP-131

Longevity / Anti-AgingPhase 3 Clinical Trials (Barth Syndrome)SubcutaneousIntravenous

A mitochondria-targeted tetrapeptide that concentrates 1000x in the inner mitochondrial membrane. Restores bioenergetics and reduces oxidative damage.

Molecular Weight

640.8 Da

Half-Life

~4 hours

Sequence

D-Arg-Dmt-Lys-Phe-NH2

Mechanism of Action

Selectively binds cardiolipin on the inner mitochondrial membrane, stabilizing electron transport chain complexes, reducing ROS production, and optimizing ATP synthesis.

Dosing Protocol

0.25 mg/kg/hr IV infusion or 40mg subcutaneous daily in clinical trials.

Open peptide calculator
Reconstitution

Research-grade: typically supplied in solution.

Storage

Refrigerate 2-8°C. Protect from light.

Side Effects
  • ●Injection site reactions
  • ●Headache
  • ●Generally well-tolerated in trials
Key Research Findings
  • ●Improved cardiac function in Barth Syndrome patients (Phase 3)
  • ●Reversed age-related mitochondrial dysfunction in preclinical models
  • ●Improved exercise tolerance in heart failure trials

Research Use Only

This information is provided for educational and research purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before using any research compounds.